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INTRODUCTION 
With the rapid advances in the field of biotechnology 
during the last decade, many peptides and proteins 
have been produced and evaluated for therapy of 
various diseases, including cancer. However, rapid 
clearance and the possibility of immunogenicity after 
the in vivo administration of these biotechnology-
driven products have impeded their marketing. To 
circumvent these problems, synthetic and natural 
polymers such as polyethylene glycol (PEG) and 
dextrans, respectively, have been covalently attached 
to proteins, and some of these protein-polymer 
conjugates have shown promising therapeutic results. 
The conjugation of proteins with polymers usually 
causes a reduction in the recognition of the protein by 
the immune system, resulting in a decrease in protein 
clearance and immunogenicity. Most of the protein-
polymer conjugates retain the pharmacologic activity 
of the protein, although to a lesser extent than the 
native protein. Additionally, in most of the examples 
in the literature, a significant increase in the plasma 
half life of the protein more than compensates for any 
reduction in the pharmacologic effects of the 
polymer-protein conjugates. Therefore, polymer 
conjugation in most cases would result in a net 
increase in the pharmacologic activity of the protein. 
The intent of this article is to review the 
pharmacokinetics and pharmacodynamics of proteins 
conjugated to PEG which is one of the most widely 
used synthetic polymers for protein conjugation. 
PHYSIOCHEMICAL PROPERTIES 
Polyethylene glycol (PEG) is a polymer with the 
structure (–CH2CH2O–)n that is synthesized normally 
by ring opening polymerization of ethylene oxide. 
The polymer is usually  linear at molecular weights 
(MWs) ≤ 10 kD. However, the higher MW PEGs 
may have some degree of branching. Polyethylene 
glycols of different MWs have already been used in 
pharmaceutical products for different reasons (e.g., 
increase in solubility of drugs). Therefore, from the 
regulatory standpoint, they are very attractive for 
further development as drug or protein carriers. 
For coupling proteins to PEG, usually monomethoxy 
PEG [CH3 (–O–CH2–CH2)n–OH] is first activated by 
means of cyanuric chloride, 1,1'-carbonyldiimidazole, 
phenylchloroformate, or succidinimidyl active ester 
(1) before the addition of the protein. In most cases, 
the activating agent acts as a linker between PEG and 
the protein, and several PEG molecules may be 
attached to one molecule of protein as depicted in 
Figure 1. Therefore, pharmacokinetics and 
pharmacodynamics of the PEG-protein conjugates 
are dependent on the MW of the PEG used for 
conjugation, the number of PEG molecules per each 
molecule of protein, and the nature of the bond 
between the protein and the linker. Interested readers 
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are referred to a comprehensive review of the PEG-
protein coupling methods by Deluged et al. (1). 
 
Figure 1. Schematic presentation of a protein-PEG 
conjugate. The number of PEG molecules per each 
protein molecule varies for different conjugates. 
IN VIVO DISPOSITION OF PEG BACKBONE 
It is believed that the kinetics of proteins attached to 
polymers are substantially affected by the kinetics of 
the polymer itself. Therefore, before reviewing 
specific PEG-protein conjugates, an analysis of the 
plasma kinetics and tissue distribution of PEGs is 
necessary. 
The plasma kinetics of PEGs are reported (2, 3) to be 
dependent on both the MW of the polymer and the 
site of injection. Yamaoka et al. (2) investigated the 
disposition of radiolabeled PEGs with MWs of 6 kD 
(PEG-6), 20 kD (PEG-20), 50 kD (PEG-50), and 170 
kD (PEG-170) after iv administration to mice. 
Similar to other polymers such as dextrans (4, 5), the 
plasma concentrations (Fig. 2) and area under the 
plasma concentration-time curves (AUCs) (Table 1) 
of higher MW PEGs were substantially greater than 
those of the lower MW polymers. Additionally, the 
half life of the polymers progressively increased as 
the MW increased from 6 kD to 170 kD (Table 1); 
the relationship between the half and the MW of 
PEGs is sigmoidal (Figure 3), which appears to be 
one of the characteristics of the kinetics of 
macromolecules. 
 
Figure 2. Blood radioactivity-time courses after iv 
administration of PEG with different molecular weights. 
Key: () PEG-170; (∆) PEG-50; () PEG-20; (❍) PEG-6. 
From Ref. (2). 
Table 1. Mean ± SD of AUC and terminal half life of 
PEGs with different MWs after iv administration to 
micea 
Parameter PEG-6 PEG-20 PEG-50 PEG-170 
AUC, 
%dose.hr/mL 
6.17 
± 2.18 
110 
± 7.17 
600 
± 11.9 
1110 
± 27.0 
t1/2, min 17.6 
± 5.90 
169 
± 20.0 
987 
± 79.0 
1390 
± 57.0 
a Source: Reference (2) 
With regard to the site of injection, PEG-50 is 
retained at the injection site longer than PEG-6 after 
im and sc injections (3), suggesting that the 
absorption of PEG from im and sc sites is MW 
dependent. However, after the ip administration, the 
injection site disappearance profiles of both MWs 
were very similar (3). 
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Figure 3. Relationship between the plasma half life of 
PEG and its molecular weight. From data presented in 
Table 1, Ref. (2). 
The differences among the plasma concentration-time 
courses of PEGs with different MWs (Fig. 2) are 
mostly due to the size of these PEGs in relation to the 
pore sizes of the vascular beds in kidneys. Chang et 
al. (6) reported that, in rats, renal elimination of 
another linear polymer, neutral dextrans, with a MW 
of ~ 10 kD occurred without any molecular 
restriction. However, the renal clearance of dextrans 
of larger MWs progressively decreased and 
approached zero at a MW of ~40 kD. This is in 
agreement with a study (2) in mice using radiolabeled 
PEG, demonstrating a sigmoidal relationship between 
the renal clearance and the log MW of PEGs. This 
type of sigmoidal relationship (2) agrees well with 
the theoretical models of renal excretion of 
macromolecules based on the pore sizes of the 
glomerular capillary wall. 
The relatively limited information on the metabolism 
of PEG in the body (7, 8) indicates that PEG 
undergoes cytochrome P-450 oxidation, resulting in 
the formation of ketone, ester, and aldehyde groups 
(8). Additionally, smaller MW PEGs are excreted 
into bile (7). 
In terms of tissue distribution, it appears that PEGs 
with MWs between 6 kD to 170 kD distribute 
insignificantly to tissues such as heart, lung, liver, 
spleen, kidney, and thyroid gland (2). However, the 
distribution of PEGs to gastrointestinal tract and 
feces is relatively substantial (2). Additionally, no 
clear MW dependency is observed for the 
accumulation of PEG in tissues (2). 
PEG-PROTEIN CONJUGATES 
During the last three decades, PEG has been 
investigated extensively for delivery of various 
proteins via parenteral routes. Some examples are 
listed below. 
Anticancer Agents 
Generally, polymers have been most widely used for 
the delivery of both traditional (small molecule) 
drugs and proteins/enzymes in the treatment of 
cancer. However, PEGs have been specifically 
investigated for the delivery of anticancer 
proteins/enzymes as discussed below.  
Antibodies: One of the major problems for the use of 
xenogenic monoclonal and polyclonal antibodies for 
the treatment of tumors is their immunogenicity 
which results in a rapid removal of the antibodies 
from the body and the possibility of allergic reactions 
after multiple administration. Kitamura et al. (9) 
conjugated the F(ab')2 fraction of the murine 
monoclonal antibody A7 to PEG 5 kD and studied 
the tumor accumulation and the kinetics of the 
conjugate in mice. The conjugate had a longer plasma 
half life and higher tumor accumulation, compared 
with the free F(ab')2 fraction. However, the tumor: 
blood ratio of the free F(ab')2 fraction was higher 
than that for the conjugate (9). 
Takashina et al. (10) studied the pharmacokinetics 
and dynamics of conjugates of monoclonal antibody 
A7 to PEG 5 kD and dextran 70 kD. In vitro studies 
showed that the conjugates retained the antigen 
binding activity of the antibody. Additionally, after 
the iv administration of the conjugated and free 
antibody, the PEG conjugate had a plasma half life 
twice of that for the free antibody (10). On the other 
hand, the dextran conjugate showed higher clearance 
and shorter half life, compared with the free and PEG 
conjugated antibody. Additionally, the tumor 
accumulation of dextran-antibody conjugate was less 
than those for the free and PEG conjugated antibody. 
This study (10) suggests that the kinetics of polymer-
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monoclonal antibody A7 are significantly dependent 
on the structure of the polymer. 
Arginase: A PEG 5 kD conjugate of arginase 
retained 65% of the activity of the enzyme and 
prolonged its plasma half life in mice after multiple 
dose therapy (11); 30 days after the start of the 
treatment, the half life of the native enzyme was 1 hr, 
while the half life of the conjugate was 12 hr. In 
terms of effects, the conjugate increased the survival 
time in mice with Taper liver tumor. However, the 
free enzyme did not show any improvement in the 
survival time (12). With regard to the effects of the 
enzyme against L5178Y mouse leukemia cells, 
whereas the conjugate was more effective than the 
native enzyme in vitro, neither was able to stop the 
growth of tumor in vivo (12). 
Asparaginase: Asparaginase, isolated from 
Escherichia Coli and Erwinia Carotovora, 
metabolizes asparagine, a necessary nutrient for 
sensitive tumors. However, after multiple injection of 
the enzyme, antibodies raised against the enzyme 
would quickly remove the enzyme from the 
circulation, and also significant immunogenicity may 
be observed. Several studies (13-19) have 
documented the usefulness of a conjugate of 
asparaginase with PEG for the treatment of various 
cancers in both humans and animals. Ho and his 
colleagues (15, 17) showed that the conjugate would 
alter the pharmacokinetics of the enzyme drastically 
in both humans and rabbits. In humans (15), 
conjugation resulted in an increase in the plasma half 
life from 20 hr (for native enzyme) to 357 hr (for the 
conjugate). In rabbits (17), the half life values of the 
free and conjugated asparaginase were 20 and 144 hr, 
respectively. The increase in the plasma half lives in 
both species was due to a significant decrease in the 
clearance of the enzyme (15, 17). The alterations in 
the kinetics of the enzyme by PEG conjugation also 
resulted in significant improvements in the toxicity 
and efficacy profile of the enzyme after in vivo 
administrations to animals (14, 16, 18) and humans 
(13, 19). A conjugate of asparaginase and PEG 
(pegaspargase) was marketed (Oncaspar) in 1994 
for the treatment of acute lymphoblastic leukemia 
(ALL) in patients who are hypersensitive to native 
forms of L-asparaginase. Oncaspar is marketed by 
Rhône-Poulenc Rorer Pharmaceuticals, Inc. in the 
U.S. and Canada. 
Methioninase: It is known that all the tumor cells 
have elevated requirement for methionine. Therefore, 
methioninase may be used in cancer therapy. 
However, the recombinant enzyme, obtained from 
bacteria, has a short plasma half life and may be 
immunogenic upon multiple dose administration. 
Very recently, Tan et al. (20) demonstrated the 
potential of a conjugate of methioninase and PEG 5 
kD in cancer therapy. In vitro tests demonstrated that 
the conjugate retained 70% activity of the enzyme. 
Additionally, in rats, the plasma half life of the 
enzyme was increased by a factor of 2 when it was 
conjugated to PEG 5 kD (20). Further, the effects of 
the conjugate lasted for 8 hr, as opposed to 2 hr for 
the free enzyme. In vitro studies in human lung and 
kidney cancer cells showed identical IC50 values for 
the conjugated and free methioninase, demonstrating 
the effectiveness of the enzyme in the conjugated 
from. Also, after the injection of the conjugate to 
tumor-bearing mice, the tumor: blood enzyme ratio 
was higher for the conjugate (1:6), compared with the 
free enzyme (1:10) administration (20). More studies 
are needed to confirm these promising findings. 
Enzyme Replacement 
Adenosine Deaminase: A deficiency of the enzyme 
adenosine deaminase (ADA) results in combined 
immunodeficiency disease (CID). For several years, 
conjugates of PEG and ADA have been used 
successfully for enzyme replacement in the treatment 
of CID in children (21-23). A conjugate of PEG and 
ADA, which is also named pegademase, was 
marketed (Adagen) by Enzon, Inc. (Piscataway, 
NJ) in the US in 1990. The outcome of therapy with 
the conjugate appears to be better than red blood cell 
transfusion (23), which is another treatment for ADA 
deficiency. Studies (21-23) have shown that weekly 
intramuscular injections of the conjugate of PEG with 
bovine ADA would reverse the symptoms of ADA 
deficiency in most cases without substantial toxicity 
or hypersensitivity. The conjugate appears to have a 
very long half life of 48-72 hr in children (21). From 
a historic perspective, the PEG-ADA conjugate 
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served as one of the earliest examples of polymer 
conjugates marketed in the US and prompted more 
research interest in this area.  
Uricase: Uricase is an enzyme which converts uric 
acid to allantoin and is lacking in humans. When the 
enzyme is administered to humans, it causes a 
significant reduction in the plasma and urine levels of 
uric acid. Therefore, it can be effective in the 
treatment of gout and other diseases related to high 
levels of urate. However, after multiple 
administration, the antibodies against this enzyme 
would deactivate it very rapidly. Several conjugates 
of uricase with PEGs (24-28) have been investigated 
to overcome this problem. Yasuda et al. (28) reported 
that conjugation of uricase with  PEG resulted in a 
decrease in antibody production and reactivity 
towards uricase. When administered intravenously to 
rats, the enzymatic activity half life of the PEG 
conjugate (~ 7 hr) was almost 10 times of that for the 
parent enzyme (0.6 hr) (28). 
 
Figure 4. Relationship between the percentage of 
amino groups of uricase modified with dextran 10 kD 
(❍) or PEG 10 kD () and the percentage of remaining 
enzymatic activity of uricase. From Ref. (28). 
The enzymatic activity of the polymer conjugated 
uricase is shown to be dependent on the degree of 
modification of the amino groups of the enzyme 
during the conjugation process (28). An increase in 
the modification would result in a decrease in the 
enzymatic activity of uricase for both dextran and 
PEG conjugates (Fig. 4). However, the decrease in 
the activity is more pronounced for the PEG 
conjugate, compared with dextran conjugation 
(Figure 4) (28). 
Antioxidant Enzymes 
Catalase: Similar to superoxide dismutase (SOD), 
catalse is an antioxidant enzyme, and several studies 
(29-32) have investigated the effects of PEG 
conjugates of SOD and catalse on the same animal 
model. The PEG-catalse conjugate was first prepared 
by Abuchowski et al. (33) using both PEG 1900 and 
5 kD. These investigators (33) demonstrated that both 
conjugates retained significant (>90%) activity of the 
enzyme and were resistant to digestion by trypsin, 
chymotrypsin, and protease. Further, the half life of 
the conjugates was long even after their repeated 
administration to mice (33). A later study (34) using 
subcutaneous osmotic pumps delivering the 
conjugate showed the conjugate’s beneficial effects 
in a rat model of lung injury due to asbestosis. 
Despite promising effects of the PEG-catalase 
conjugate, recent work in this area has concentrated 
more on a conjugate of SOD and PEG described 
below.  
Superoxide Dismutase (SOD): Among the 
conjugates of PEG, SOD is the most widely studied. 
Superoxide dismutase is an antioxidant enzyme 
which eliminates superoxide anion, reducing tissue 
injury. After its iv administration in animals, the 
plasma half life of the enzyme is very short (5-10 
min). Several investigators have reported the effects 
of conjugation of SOD with PEG on the 
pharmacokinetics and dynamics of the enzyme, some 
of which are summarized in Table 2 (29-32, 35-47). 
Although some of these studies have compared the 
effects of PEG-SOD with those of the free enzyme, 
most of the studies have concentrated on the effects 
of PEG-SOD without a comparison with the free 
SOD (Table 2). There is little doubt that conjugation 
of SOD with PEG increases its plasma half life (35) 
and reduces its immunogenicity (29, 35). However, 
conflicting reports (30-32, 36-40, 43, 45-47) exist 
with regard to the effects of PEG-SOD in various 
animal models of injury. Additionally, the results of 
clinical trials (42, 44) with PEG-SOD have not been 
unequivocal. 
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Table 2. Some of studies on the conjugates of PEG and SOD. 
Type of Study Comments Reference 
In vitro and in vivo kinetics and dynamics in 
rats 
PEG 5 kD conjugate retained 51% enzyme activity; 
plasma half life of conjugate was longer than the native 
SOD after repeated dosing; anti-inflammatory effect of 
the conjugate was higher than SOD. 
(35) 
In vivo immunogenicity in mice Decreased immunogenicity; antibody titer to the 
conjugate was 0.03%-0.07% of that observed with SOD. 
(29) 
In vivo effects in endotoxemia in pigs No beneficial effects (30) 
In vivo effects in a dog model of ischemia/ 
reperfusion 
Conflicting results: both no effect (37) or a reduction 
(36) in heart injury associated with reperfusion have been 
reported. 
(36, 37) 
In vivo effects in a rat model of brain 
ischemia 
Administration of PEG-SOD before induction of focal 
cerebral ischemia resulted in a reduction in brain injury.  
(31) 
In vivo effects in a rabbit model of ischemia/ 
reperfusion 
No effect in heart injury associated with reperfusion. (38) 
In vivo distribution into brain of piglets IV injection of PEG-SOD did not increase the enzyme 
level in the brain in control piglets and in animals 
subjected to global ischemia/reperfusion. 
(39) 
In vivo effects in hemorrhagic shock in rats Administration of a PEG-SOD conjugate to a rat model 
increased survival from 25% to 67%. 
(40) 
In vivo brain distribution in rats The concentrations of PEG-SOD in the brain and CSF of 
normal rats were low; brain and CSF concentrations were 
higher after hypertensive brain injury 
(41) 
In vivo effects in piglets with hypoxic brain 
injury 
Administration of PEG-SOD 5 min after reoxygenation 
did not have any positive effects. 
(32) 
Phase II clinical trial study in severe head 
injury 
Improved outcome at 3 and 6 months after the treatment 
with PEG-SOD (10,000 U/kg), compared with placebo. 
(42) 
In vivo study in rats with oxygen toxicity Insufflation of PEG-SOD increased survival time, in 
comparison with both placebo and free SOD.  
(43) 
Clinical trial in severe head injury Percent of patients in a vegetative state or dead at 3 and 6 
months postinjury was lower after the conjugate, 
compared with placebo. 
(44) 
In vivo effect in a rat model of ischemic 
renal failure 
The PEG-SOD was more effective than an equivalent 
dose of free SOD. 
(45) 
In vivo effects in a rat model of warm renal 
ischemia 
PEG-SOD conjugates were more protective, compared 
with free SOD. 
(46) 
In vivo effects in a rat model of 
ischemia/reperfusion 
SOD conjugated to PEG showed a superior effect over 
that conjugated to polyacryloylmorpholine. 
(47) 
   
Thrombolytic Agents 
Streptokinase: Rajagopalan et al. (48) conjugated 
streptokinase to PEG 2 kD, 4 kD, and 5 kD, and 
investigated the thrombolytic activity and 
antigenicity of the conjugates. In vitro studies 
demonstrated comparable activity for the conjugates 
and the free enzyme. However, the binding of the 
conjugates to antibodies against streptokinase was 
reduced by 95% (48). In vivo studies in mice (48, 49) 
revealed low clearance of the conjugates attached to 
plasmin, resulting in a half life of 200 min for the 
conjugate, compared to a half life of 15 min for 
streptokinase itself. These studies (48, 49) 
demonstrate that PEG conjugation of streptokinase 
retains the activity of the enzyme, prolongs its plasma 
circulation by blocking plasmin degradation, and 
reduces the antigenicity of the enzyme. 
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Urokinase: In dogs, a conjugate of urokinase, a 
thrombolytic agent, with PEG 5 kD was shown (50) 
to have longer activity and more activation of 
fibrinolysis, compared with the native enzyme. Also, 
a polypropylene glycol-PEG conjugate of urokinase 
showed a decreased activity on plasminogen and had 
a longer plasma half life in rabbits, compared with 
the native enzyme (51). Later (52), it was shown that 
this conjugate blocked autolysis of the enzyme at 
370C. Unfortunately, these early positive results have 
not been followed by more extensive in vivo studies. 
Oxygen Carriers 
Hemoglobin: Several studies have examined the 
feasibility of the conjugation of hemoglobin to PEG 
for use as a blood substitute. Hemoglobin binds to 
oxygen and can be used as an oxygen carrier. 
However, because of its rapid elimination, the plasma 
half life of the protein is very short. Additionally, the 
affinity of hemoglobin to oxygen is too high for 
release of oxygen in the tissues. A conjugate of PEG 
with pyridoxylated hemoglobin has been shown (53, 
54) to have longer plasma half life and better 
therapeutic effects in rats, compared with the free 
hemoglobin. The benefits of PEG-hemoglobin 
conjugates as a blood substitute have been shown in 
several animal models, including a hemorrhagic 
hypotension pig model (55) and in partial exchange 
transfusion and top-loaded rat models (56). 
Additionally, a PEG-hemoglobin conjugate has been 
used (57) for an increase in the sensitivity of tumors 
to radiation by increasing oxygen delivery to the 
tumor. These studies point to the potential of 
hemoglobin conjugated to PEG for manipulation of 
the oxygen levels in normal and malignant tissues. 
Cytokines and Hematopoietic Growth Factors 
Interleukin-2 (IL-2): Both animal and clinical 
studies have been conducted using PEG conjugates of 
IL-2. Earlier studies in animals (58, 59) and humans 
(60) showed that PEG conjugation would increase 
stability, decrease clearance, and increase plasma half 
life (> 20 fold) of IL-2. Further, these studies (58-61) 
suggested promising effects for the PEG-IL-2 
conjugate in the treatment of various cancers. 
However, more recent data (62-64), mostly in 
patients, have failed to clearly demonstrate an 
advantage for PEG-IL-2, compared with free IL-2, in 
terms of therapeutic or toxic end points for the 
treatment of cancer. On the other hand, it appears that 
recent interest in the PEG-IL-2 conjugate revolves 
around its potential beneficial effects in patients with 
human immunodeficiency virus (65-69). Recent 
studies (65-69) in patients with HIV show that low 
dose PEG-IL-2, alone or in combination with 
zidovudine, would increase the immune response by 
increasing the number of CD4 T cells without 
significant toxicity. Additional clinical studies, 
comparing free and PEG conjugated IL-2 will shed 
more light on these exciting results. 
Recombinant human granulocyte colony-
stimulating factor (rhG-CSF): This is a 156 amino 
acid glycoprotein which is produced by Escherichia 
Coli and increases production and phagocytic and 
cytotoxic activities of neutrophils (70). The plasma 
half life of rhG-CSF is short (3.5 hr) (70), requiring 
daily injections to sustain the neutrophil levels in 
situations like cancer chemotherapy. In 1991, Tanaka 
et al. (71) reported that a conjugate of  rhG-CSF with 
PEG increased the plasma half life of the growth 
factor from 1.8 hr (native factor) to 7 hr (conjugated 
factor) in mice. The increase in half life was 
associated with an increase in both the intensity and 
duration of the effect of the drug on the neutrophil 
count (71). These results were later (72) confirmed in 
mice made neutropenic by the administration of 
anticancer agents cyclophosphamide and fluorouracil. 
Recent studies (73-75) demonstrated that the in vivo 
activity of the conjugate is dependent on both the 
MW of PEG (73, 74) and the total number of PEG 
units attached to rhG-CSF (73, 75);  there was a 
positive relationship between the total mass of the 
conjugate and the intensity and duration of the effect 
of rhG-CSF. Future studies should be conducted to 
determine whether these positive results in animals 
can be extended to humans. 
Recombinant human granulocyte/macrophage 
colony-stimulating factor (rhGM-CSF): This is a 
127 amino acid glycoprotein produced in yeast which 
acts similar to rhG-CSF to increase neutrophils, with 
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a broader action on monocytes, macrophages, and 
eosinophils (70). Similar to rhG-CSF, the plasma half 
life of rhGM-CSF is short (2-3 hr) (70), requiring 
daily injections to sustain the neutrophil levels in 
patients undergoing bone marrow transplantation or 
intensive chemotherapy. Compared with rhG-CSF, 
the studies on the conjugates of PEG with rhGM-CSF 
are scarce (76, 77). The limited information indicates 
that similar to rhG-CSF, PEG conjugation increases 
the plasma half life (76) and some biological 
activities of rhGM-CSF (77). 
Other Proteins 
Table 3 lists the use of PEGs for delivery of some 
other therapeutic agents  (78-86) which are not 
discussed in detail in this review. These studies 
(Table 3) show that polymer conjugation could result 
in altered pharmacokinetics, decreased affinity of the 
conjugate to bind to the protein receptor, and/or a 
decrease in antigenicity of proteins. 
CONCLUDING REMARKS 
The examples provided in this review clearly point to 
the potential advantages of polyethylene glycols for 
parenteral delivery of proteins. Despite significant 
promise of protein therapeutics in cell culture and 
other in vitro studies, optimal delivery of these agents 
in humans is very challenging. This is mostly because 
of relatively high clearance and short plasma half life 
of these agents, especially after multiple 
administration which results in activation of the 
immune system and faster elimination of the proteins. 
The available studies on the use of PEG for delivery 
of proteins indicate that these polymers will continue 
to have a significant role in the delivery of proteins in 
the future. 
Table 3. Additional studies on the conjugates of PEGs 
with proteins 
Drug/Protein Description 
Antigen E A preliminary study in man showed that 
a 5 kD conjugate may be useful for the 
immunotherapy of ragweed hay fever 
(78). 
Batroxobin A 10 kD conjugate retained the activity 
of the enzyme while losing its ability to 
bind to anti-batroxobin antibodies in 
dogs (79). 
Bilirubin 
oxidase 
In a rat model of jaundice, the conjugate 
reduced the blood and liver levels of 
bilirubin, but, did not improve the liver 
function tests (80). 
Honeybee 
Venom 
In a clinical study, a 5.7 kD conjugate 
showed lower systemic reactions during 
immunotherapy and less efficacy against 
honeybee sting (81).  
Interferon-
alpha 
In humans, the half life of the conjugate 
was twice as long as that of free protein; 
however, this did not result in a 
substantial reduction in the frequency of 
the protein administration (82). 
Interferon-
gamma 
A 5 kD conjugate had activity similar to 
that of free protein but with a reduced 
binding affinity; the plasma half life of 
the conjugate was significantly longer 
than that of free protein in rats (83).  
Interleukin-6 A 12 kD conjugate showed significantly 
higher thrombopoietic effects (increase 
in the platelet counts), compared with 
free IL-6 in mice (84)  
Tissue 
Plasminogen 
Activator 
In mice, the half life of radioactivity 
after the injection of the radiolabeled 
conjugate with 5 kD and 20 kD was 
long; however, the effect disappeared 
much faster (85). 
Trypsin A 5 kD conjugate was resistant to anti-
trypsin antibody precipitation and 
retained some of the activities of trypsin 
to varying degrees (86).  
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